Press Room

Continuous Manufacturing of Oral Solid Dosage Forms

Start
Tuesday, April 16, 2024
End
Thursday, April 18, 2024
Location: Portugal
Continuous Manufacturing of Oral Solid Dosage Forms_Hovione

Continuous manufacturing holds the promise of improved efficiency, enhanced quality, greater operational flexibility and accelerated development. At Hovione we are proud to be at the forefront of this industry transition and excited to join leading individuals from industry, academia and regulatory agencies at the ECA Conference on “Continuous Manufacturing of Oral Solid Dosage Forms”. 

Register today

and take advantage of the unique opportunity to visit Hovione's cutting-edge labs and continuous tableting manufacturing facilities in Lisbon, Portugal 

 

The objective of this event is to share the practical experience and the potential of continuous manufacturing for oral solid dosage forms, also known as Continuous Tableting:

  • Regulatory Requirements
  • Industry Experience
  • Technological Opportunities
  • Latest research

Speakers

  • Selma Celikovic, RCPE
  • Prof Dr Alastair Florence, CMAC
  • Joshua Hanson, Eli Lilly
  • Dr Doug Hausner, Thermofisher Scientific
  • Dr Jim Holman, GEA
  • Dr Adrian Kape, Glatt
  • Dr Sau (Larry) Lee, FDA
  • Prof Dr Jim Litster, University of Sheffield
  • Dr Robert Meyer, MSD
  • Dr José Luís Santos, Hovione
  • Wayne Sinclair, TEVA
  • Jan Verelst, Siemens

More about the Conference, Speakers and Programme

More about Hovione Site Visit:
As part of the conference, registered participants will have a unique opportunity to visit Hovione's cutting-edge labs and manufacturing facilities in Lisbon, where research, development, and manufacturing activities take place.

In the labs, participants will gain access to Particle Engineering facilities, explore some of the most advanced analytical PAT tools, and get a close look at the specialized equipment used in continuous tableting development. They will also have the chance to observe analytical and process development operations in an engaging hands-on workshop, guided by Hovione experts.

During the visit to the manufacturing facilities, participants will witness a state-of-the-art facility in action, showcasing a continuous direct compression production unit. Additionally, they will have the opportunity to see and compare with an equivalent batch process.
Please note that availability for this exclusive site visit is limited, so securing your spot early is highly recommended to ensure you don't miss out on this opportunity to experience Pharmaceutical innovation at Hovione.

  • We provide bus transfer from the conference hotel to the Hovione sites. After the site visit there will be transfers to the airport and back to the conference hotel.
  • Due to competition reasons, individual participants may be excluded from the site visit
  • Participants are required to sign a Confidential Disclosure Agreement (CDA) before entering Hovione sites

More about the ECA Academy:
The ECA Academy is the educational organisation established by the ECA Foundation. It develops and organises a wealth of international education courses, conferences (also as part of a GMP Certification Programme) and webinars around GMP and regulatory compliance, picking up emerging GMP challenges and currently discussed subjects. While courses and webinars are designed to provide continuous education for GMP professionals in production, quality control, quality assurance etc, European conferences are organised as discussion forums on new trends and developments.

If you have any questions about the Conference:
Tel.: +49 (0)6221 / 84 44 0 
www.gmp-compliance.org

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026